Form 8-K First Wave BioPharma, For: Jul 05
Exhibit 16.1
July 7, 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by First Wave BioPharma, Inc. under Item 4.01 of its Form 8-K dated July 5, 2022. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of First Wave BioPharma, Inc. contained therein.
Very truly yours,
/s/ Marcum llp
Marcum llp
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
- Ashley Provides Historical Drilling Summary of Sahara Utah Uranium-Vanadium Property
- Schneider Electric Sustainability Impact Program Continues Progressing in Q1 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!